Non-Hodgkin lymphoma natural history, complications and prognosis: Difference between revisions
(Created page with "{{Non-Hodgkin lymphoma}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{Hematology}} {{Hematological malignancy histology}} {{SIB}} [[bn:অ-হজকিনের ল...") |
|||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
== | |||
==Prognosis== | |||
{{see also|International Prognostic Index}} | |||
The most significant factor in overall [[prognosis]] is the grade, or aggressiveness, of the lymphoma. Indolent (low-grade) non-Hodgkin's lymphoma is generally not curable, but is typically slowly progressive and responds temporarily to therapy. Aggressive and highly aggressive (intermediate- and high-grade) NHL's are potentially curable with combination [[chemotherapy]]. Long-term survival or cure rates for these diseases vary with a number of prognostic factors. | |||
===International Prognostic Index=== | |||
The [[International Prognostic Index]], or IPI, is the most widely used prognostic system for non-Hodgkin's lymphoma. This system uses 5 factors: | |||
:*Age | |||
:*[[Lactate dehydrogenase]] level (a blood test) | |||
:*Performance status | |||
:*Clinical stage | |||
:*Sites of extranodal disease | |||
However, it should be noted that the IPI was developed prior to the introduction of [[rituximab]]. As [[rituximab]] has become a standard part of therapy for [[B-cell]] NHL's, the impact on the prognostic value of the IPI is unclear. | |||
====FLIPI==== | |||
For the subtype of NHL known as [[follicular lymphoma]], a modified version of the IPI called the FLIPI ([[International Prognostic Index|follicular lymphoma international prognostic index]]) has been developed. The factors which figure into the FLIPI are age, clinical stage, [[lactate dehydrogenase]] level, [[hemoglobin]] level, and number of nodal sites involved. As with the IPI, the FLIPI was developed and validated prior to the widespread use of [[rituximab]], so the same caveats apply as were mentioned with the IPI above. | |||
==References== | ==References== | ||
Revision as of 21:40, 20 January 2012
|
Non-Hodgkin lymphoma Microchapters |
|
Differentiating Non-Hodgkin's Lymphoma |
|---|
|
Treatment |
|
Case Studies |
|
Non-Hodgkin lymphoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Non-Hodgkin lymphoma natural history, complications and prognosis |
|
FDA on Non-Hodgkin lymphoma natural history, complications and prognosis |
|
CDC on Non-Hodgkin lymphoma natural history, complications and prognosis |
|
Non-Hodgkin lymphoma natural history, complications and prognosis in the news |
|
Blogs on Non-Hodgkin lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Prognosis
The most significant factor in overall prognosis is the grade, or aggressiveness, of the lymphoma. Indolent (low-grade) non-Hodgkin's lymphoma is generally not curable, but is typically slowly progressive and responds temporarily to therapy. Aggressive and highly aggressive (intermediate- and high-grade) NHL's are potentially curable with combination chemotherapy. Long-term survival or cure rates for these diseases vary with a number of prognostic factors.
International Prognostic Index
The International Prognostic Index, or IPI, is the most widely used prognostic system for non-Hodgkin's lymphoma. This system uses 5 factors:
- Age
- Lactate dehydrogenase level (a blood test)
- Performance status
- Clinical stage
- Sites of extranodal disease
However, it should be noted that the IPI was developed prior to the introduction of rituximab. As rituximab has become a standard part of therapy for B-cell NHL's, the impact on the prognostic value of the IPI is unclear.
FLIPI
For the subtype of NHL known as follicular lymphoma, a modified version of the IPI called the FLIPI (follicular lymphoma international prognostic index) has been developed. The factors which figure into the FLIPI are age, clinical stage, lactate dehydrogenase level, hemoglobin level, and number of nodal sites involved. As with the IPI, the FLIPI was developed and validated prior to the widespread use of rituximab, so the same caveats apply as were mentioned with the IPI above.
References
Template:SIB bn:অ-হজকিনের লসিকার্বুদ de:Non-Hodgkin-Lymphom nl:Non-Hodgkin fi:Non-Hodgkinin lymfooma sv: Non-Hodgkins lymfom